AU2005226731A1 - Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase - Google Patents

Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase Download PDF

Info

Publication number
AU2005226731A1
AU2005226731A1 AU2005226731A AU2005226731A AU2005226731A1 AU 2005226731 A1 AU2005226731 A1 AU 2005226731A1 AU 2005226731 A AU2005226731 A AU 2005226731A AU 2005226731 A AU2005226731 A AU 2005226731A AU 2005226731 A1 AU2005226731 A1 AU 2005226731A1
Authority
AU
Australia
Prior art keywords
ampk
ischemic
stroke
pampk
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005226731A
Other languages
English (en)
Inventor
Hong Li
Louise D. Mccullough
Jill Mcfadden
Gabriele V. Ronnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Fasgen LLC
Original Assignee
Johns Hopkins University
Fasgen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Fasgen LLC filed Critical Johns Hopkins University
Publication of AU2005226731A1 publication Critical patent/AU2005226731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2005226731A 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase Abandoned AU2005226731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55600004P 2004-03-24 2004-03-24
US60/556,000 2004-03-24
PCT/US2005/009797 WO2005092068A2 (en) 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase

Publications (1)

Publication Number Publication Date
AU2005226731A1 true AU2005226731A1 (en) 2005-10-06

Family

ID=35056772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005226731A Abandoned AU2005226731A1 (en) 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase

Country Status (11)

Country Link
US (1) US8293791B2 (enExample)
EP (1) EP1734973A4 (enExample)
JP (1) JP2008504228A (enExample)
KR (2) KR101283416B1 (enExample)
CN (1) CN101132802A (enExample)
AU (1) AU2005226731A1 (enExample)
BR (1) BRPI0509085A (enExample)
CA (1) CA2560843A1 (enExample)
IL (1) IL178242A0 (enExample)
MX (1) MXPA06010916A (enExample)
WO (1) WO2005092068A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504228A (ja) 2004-03-24 2008-02-14 ファスジェン・リミテッド・ライアビリティ・カンパニー Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法
WO2014160989A2 (en) 2013-03-28 2014-10-02 The Trustees Of Columbia University In The City Of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
KR101152607B1 (ko) 2005-12-20 2012-06-05 에스케이케미칼주식회사 ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
KR101532211B1 (ko) * 2014-04-30 2015-06-30 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법
CN119868551A (zh) * 2024-11-28 2025-04-25 四川大学华西医院 F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
JP2008504228A (ja) 2004-03-24 2008-02-14 ファスジェン・リミテッド・ライアビリティ・カンパニー Ａｍｐ活性化プロテインキナーゼの薬理学的阻害による新規神経保護方法

Also Published As

Publication number Publication date
IL178242A0 (en) 2007-03-08
CA2560843A1 (en) 2005-10-06
EP1734973A2 (en) 2006-12-27
EP1734973A4 (en) 2010-08-04
WO2005092068A3 (en) 2007-09-20
JP2008504228A (ja) 2008-02-14
KR20120078756A (ko) 2012-07-10
BRPI0509085A (pt) 2007-08-21
MXPA06010916A (es) 2007-07-25
CN101132802A (zh) 2008-02-27
KR101283416B1 (ko) 2013-07-08
KR20070085093A (ko) 2007-08-27
US20090137665A1 (en) 2009-05-28
US8293791B2 (en) 2012-10-23
WO2005092068A2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
McCullough et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke
US20250360129A1 (en) Compositions and methods of using tyrosine kinase inhibitors
Grimm et al. CaMKIIδ mediates β-adrenergic effects on RyR2 phosphorylation and SR Ca2+ leak and the pathophysiological response to chronic β-adrenergic stimulation
Zegallai et al. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets
Hurtado et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport
Kim et al. A small molecule AMPK activator protects the heart against ischemia–reperfusion injury
Li et al. Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy
Eskew et al. Cellular protection mechanisms against extracellular heme: heme-hemopexin, but not free heme, activates the N-terminal c-Jun kinase
Ježek et al. Distinctions and similarities of cell bioenergetics and the role of mitochondria in hypoxia, cancer, and embryonic development
Griffiths Mitochondria and heart disease
Ruan et al. Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury
Kuwana et al. The phosphoinositide-3 kinase γ–Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity
van Mil et al. Teratogenicity and underlying mechanisms of homocysteine in animal models: a review
Saito et al. Molecular mechanisms and clinical implications of multiple forms of mitophagy in the heart
JP4387101B2 (ja) 糖尿病性網膜症の予防または処置のための網膜細胞アポトーシス抑制剤の使用
Takada et al. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis
Bright et al. δPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo
CA3045883C (en) Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
Baker et al. Targeting cellular energy production in neurological disorders
US8293791B2 (en) Method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase
Ciocci Pardo et al. Myocardial and mitochondrial effects of the anhydrase carbonic inhibitor ethoxzolamide in ischemia‐reperfusion
ES2992725T3 (en) Glycolic acid and/or d-lactic acid for the treatment of neurodegenerative diseases
Park et al. Differential cell death and Bcl-2 expression in the mouse retina after glutathione decrease by systemic D, L-buthionine sulphoximine administration
HK1118217A (en) Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
WO2007050585A2 (en) Use of a nitric oxide synthase modulator for the treatment of cardiac indications

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted